← Fulgent Genetics, Inc. (FLGT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Fulgent Genetics, Inc. (FLGT)
Services-Medical Laboratories · market cap $589M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-06 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Fulgent Genetics (FLGT) is a medical laboratory services company with a $557M market cap, 1,313 employees, and a pipeline asset FID007 in Phase 2 for Head and Neck Squamous Cell Carcinoma. The company's revenue has collapsed from a COVID-era peak of $993M in 2021 to $323M in 2025, with persistent net losses since 2022 and only $23.4M in reported cash.
The catalyst path
- 2026-11-06 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| FID007 | Phase 2 | Head and Neck Squamous Cell Carcinoma |
Price & technical context
3-month
-0.3%
6-month
+26.8%
12-month
-9.3%
52-wk range
$13.79–$30.85
vs 50-day MA
+6.5%
vs 200-day MA
+6.6%
Realized vol
66.1%
Max drawdown
-55.3%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for FLGT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.